ADR Biomedical Holdings Inc.
Stock Price Chart
2026/11/20 20:23 UpdatedPrice Trend
2026/11/20 20:23 UpdatedPrice & Trading Details
2026/11/20 20:23 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/11/01Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,145M | ¥1,560M | ¥122M | ¥51M |
| Gross Profit | ¥1,269M | ¥1,293M | -¥6M | ¥11M |
| Operating Income | -¥794M | -¥773M | -¥807M | -¥906M |
| Pretax Income | -¥1,037M | -¥857M | -¥2,071M | -¥379M |
| Net Income | -¥1,060M | ¥138M | -¥2,140M | -¥397M |
| EPS | -¥118.71 | ¥15.42 | -¥239.70 | -¥44.46 |
| Operating Margin | -37.04% | -49.52% | -660.28% | -1,777.23% |
| Balance Sheet | ||||
| Total Assets | ¥14,092M | ¥5,816M | ¥3,538M | ¥368M |
| Total Equity | ¥2,653M | ¥2,791M | ¥631M | ¥22M |
| Total Liabilities | ¥11,439M | ¥3,026M | ¥2,907M | ¥346M |
| Cash | ¥1,123M | ¥1,038M | ¥256M | ¥126M |
| Interest-bearing Debt | ¥8,507M | ¥2,472M | ¥2,648M | ¥0M |
| Equity Ratio | 18.82% | 47.98% | 17.82% | 5.98% |
| D/E Ratio | 3.21 | 0.89 | 4.20 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥40M | -¥1,152M | -¥987M | -¥785M |
| Investing CF | -¥283M | ¥8,690M | ¥23M | ¥2,979M |
| Financing CF | ¥294M | -¥7,173M | ¥172M | -¥2,322M |
| Free CF | -¥198M | -¥1,168M | -¥995M | -¥785M |
| Efficiency | ||||
| ROE | -39.96% | 4.95% | -339.41% | -1,801.98% |
| ROA | -7.52% | 2.38% | -60.50% | -107.84% |
Latest IR Information
-
Notice Regarding Commencement of a New Business
Commencing a new business for the sale of pharmaceuticals and medical supplies. Scheduled to start in December 2026, and sales for the fiscal year ending March 2027 are expected to exceed the medium-term plan by approximately 350 million yen. No...
Read more -
Notice of New Orders for High-Concentration Exosome Component Solution "NeoCella" Related Products
ADR Therapeutics, a consolidated subsidiary, secured a new order for NeoCella-related products. Total orders amount to 11,000 sets, with delivery scheduled for 2026-11-16. Sales are expected to correspond to 20% of the prior fiscal year’s net sales and will be...
Read more -
ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
Due to establishment of domestic mass-production systems and the full-scale commercial launch of the Celuration centrifuge and Celuration cell therapy kits, interim sales for the fiscal year ending March 2027 increased to 66 million yen, up 262.7% year-over-year. Operating loss...
Read more -
ADR Biomedical Holdings Inc. Disclosure: Notice of Commencement of Clinical Trial for Severe Limb Ischemia Treatment
A subsidiary resolved to commence a clinical trial of an ADRC-based therapy derived from adipose tissue targeting severe limb ischemia. Consultation on the clinical trial protocol with the PMDA has been completed, and the joint research agreement with Nagoya University...
Read more -
Notice Regarding Approval for Insurance Coverage of the Male Stress Urinary Incontinence Treatment Medical Device "Celusion Cell Therapy Kit SUI"
The Company announces that Celusion Cell Therapy Kit SUI, a male stress urinary incontinence treatment medical device manufactured and marketed by subsidiary ADR Therapeutics, has been formally approved for insurance coverage as of September 16, 2026, following a provisional designation...
Read more
Latest News (5 items)
Company Information
About
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, meniscus repair, stress urinary incontinence scleroderma, vocal cord repair, liver cirrhosis, and other diseases. In addition, it provides real estate services. The company was formerly known as ADR120S, Inc. and changed its name to ADR Biomedical Holdings Inc. in July 2026. ADR Biomedical Holdings Inc. was incorporated in 2004 and is headquartered in Chiyoda, Japan.